title: Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.
abstract: Factor H-associated hemolytic uremic syndrome (HUS) is a genetic form of thrombotic microangiopathy characterized by deficient factor H (HF-1) levels/activity and uncontrolled complement activation. The disorder mostly leads to end-stage renal disease and often recurs after kidney transplantation. We previously demonstrated that in a child with HF-1-associated HUS a simultaneous kidney and liver transplantation restored the defective HF-1 with no recurrence of the disease in the transplanted kidney. Here we describe a second childhood case of HF-1-associated HUS treated by combined kidney and liver transplant and complicated by a fatal, primary non-function of the liver graft. Graft hypoperfusion during surgery triggered ischemia/reperfusion changes and complement activation. Conceivably, as a result of defective complement regulatory potential, massive shedding of vascular heparan sulfates was documented in the transplanted liver. This might have impaired the physiological thromboresistance of vascular endothelium ending with widespread microvascular thrombosis and infarction. This case indicates that more fundamental research is needed before combined liver and kidney transplant is considered an option for children with HF-1-associated HUS.
authors.affiliation: Department of Medicine and Transplantation, Ospedali Riuniti, Bergamo, Italy. gremuzzi@marionegri.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Remuzzi
authors.forename: Piero
authors.initials: P
authors.lastname: Ruggenenti
authors.forename: Michele
authors.initials: M
authors.lastname: Colledan
authors.forename: Bruno
authors.initials: B
authors.lastname: Gridelli
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bertani
authors.forename: Paola
authors.initials: P
authors.lastname: Bettinaglio
authors.forename: Sara
authors.initials: S
authors.lastname: Bucchioni
authors.forename: Aurelio
authors.initials: A
authors.lastname: Sonzogni
authors.forename: Ezio
authors.initials: E
authors.lastname: Bonanomi
authors.forename: Valter
authors.initials: V
authors.lastname: Sonzogni
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Platt
authors.forename: Norberto
authors.initials: N
authors.lastname: Perico
authors.forename: Marina
authors.initials: M
authors.lastname: Noris
mesh_terms: D003167:Complement Activation; D017242:Complement Factor H / Q000096:biosynthesis / Q000235:genetics*; D004730:Endothelium, Vascular / Q000378:metabolism; D005091:Exons; D017809:Fatal Outcome; D005260:Female; D006084:Graft Rejection; D006463:Hemolytic-Uremic Syndrome / Q000401:mortality* / Q000628:therapy*; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D007223:Infant; D016030:Kidney Transplantation / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D017093:Liver Failure / Q000401:mortality; D016031:Liver Transplantation / Q000009:adverse effects*; D020125:Mutation, Missense; D010477:Perfusion; D015427:Reperfusion Injury
chemical_list: D017242:Complement Factor H; D006497:Heparan Sulfate; C493495:CFH protein, human